Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis

Molecular Carcinogenesis

Volumn 50, Issue 2, 2011, Pages 67-72

  Manalo, Katrina B ^a   Choong, Peter F M ^a,b   Dass, Crispin R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Cancer; Therapy; Tumorigenesis

Indexed keywords

ANGIOPOIETIN 2; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL MIGRATION; CELL SURVIVAL; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; METASTASIS; NEOPLASM; OSTEOSARCOMA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; EYE PROTEINS; FEMALE; HUMANS; MALE; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 78651423549     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20711     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;50:225-249.
2. Jemal A, Thun M, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-1694.
3. Glass A, Lacey J, Carreon DJ, Hoover RN. Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-1161.
4. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA 2002;287:2106-2112.
5. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-1416.
6. Sleeman J, Steeg PS. Cancer metastasis as a therapeutic target. EJC 2010;46:1177-1180.
7. Pepper JW, Findlay CS, Kassen R, Spencer SL, Maley C. Cancer research meets evolutionary biology. Evol Appl 2009;2:62-70.
8. Folkman J. Fighting cancer by attacking its blood supply. Sci Am 1996;275:150-154.
9. Dass CR, Ek E, Choong P. PEDF as an emerging therapeutic candidate for osteosarcoma. Curr Cancer Drug Targets 2008;8:683-690.
10. McDougall SR, Anderson AR, Chaplain MA. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: Clinical implications and therapeutic targeting strategies. J Theor Biol 2006;241:564-589.
11. North S, Moenner M, Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 2005;218:1-14.
12. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410.
13. Gordon MS, Mendelson DS, Kato G. Tumor angiogenesis and novel antiangiogenic strategies. Int J Cancer 2010;126:1777-1787.
14. Heckman-Stoddard BM, Vargo-Gogola T, McHenry PR, et al. Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression. Breast Cancer Res 2009;11:R61.
15. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006;2:178-188.
16. Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res 2007;74:100-113.
17. Ta HT, Dass C, Choong PF, Dunstan DE. Osteosarcoma treatment: State of the art. Cancer Metastasis Rev 2009;28:247-263.
18. Shi D, Xie F, Zhai C, Stern JS, Liu Y, Liu SL. The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells. Mol Cancer 2009;8:32.
19. Jain R. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
20. Spitz D. Glucose deprivation-induced oxidative stress in human tumor cells. Ann NY Acad Sci 2000;899:349-362.
21. Kalluri R. Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-433.
22. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109:227-241.
23. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000.
24. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005;97:512-523.
25. Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. Recent Results Cancer Res 2010;180:103-114.
26. Le Bourhis X, Romon R, Hondermarck H. Role of endothelial progenitor cells in breast cancer angiogenesis: From fundamental research to clinical ramifications. Breast Cancer Res Treat 2010;120:17-24.
27. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-1201.
28. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007;19:2003-2012.
29. Lee HT, Chang YC, Tu YF, Huang CC. VEGF-A/VEGFR-2 signaling leading to cAMP response element-binding protein phosphorylation is a shared pathway underlying the protective effect of preconditioning on neurons and endothelial cells. J Neurosci 2009;29:4356-4368.
30. Rydén L, Linderholm B, Nielsen NH, Emdin S, Jönsson PE, Landberg G. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 2003;82:147-154.
31. Broadhead ML, Becerra SP, Choong PF, Dass CR. The applied biochemistry of PEDF and implications for tissue homeostasis. Growth Factors 2010;28:280-285.
32. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999;285:245-248.
33. Phung M, Dass CR. In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development. J Pharm Pharmacol 2006;58:153-160.
34. Ek ET, Dass C, Choong P. PEDF: A potential molecular therapeutic target with multiply anticancer activities. Trends Mol Med 2006;12:497-502.
35. Bouck N. PEDF: Anti-angiogenic guardian of ocular function. Trends Mol Med 2002;8:330334.
36. Elayappan B, Ravinarayannan H, Pasha SP, Lee KJ, Gurunathan S. PEDF inhibits VEGF- and EPO-induced angiogenesis in retinal endothelial cells through interruption of P13K/Akt phosphorylation. Angiogenesis 2009;12:313-324.
37. Ho TC, Chen SL, Yang YC, Liao CL, Cheng HC, Tsao YP. PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilican vein endothelial cells. Cardiovasc Res 2007;76:213-223.
38. Yang H, Cheng R, Liu G, et al. PEDF inhibits growth of retinoblastoma by anti-angiogenic activity. Cancer Sci 2009;100:2419-2425.
39. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor-1. J Biol Chem 2006;281:3604-3613.
40. Ek ET, Dass C, Contreras KG, Choong PF. Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Mets 2007;24:93-106.
41. Broadhead ML, Dass C, Choong P. In vitro and in vivo biological activity of PEDF against a range of tumors. Expert Opin Ther Targets 2009;13:1429-1438.
42. Zhou XY, Liao Q, Pu YM, et al. Ultrasound-mediated microbubble delivery of pigment epithelium-derived factor gene into retina inhibits choroidal neovascularization. Chin Med J (Engl) 2009;122:2711-2717.
43. Dass CR, Contreras K, Dunstan DE, Choong PF. Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma. Biomaterials 2007;28:3026-3033.
44. Ta H, Dass CR, Larson I, Choog PFM, Dunstan DE. A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma. Biomaterials 2009;30:3605-3613.
45. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004;4:S62-S68.
46. Aita M, Fasola G, Defferrari C, et al. Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2008;68:183-196.
47. Goldfarb SB, Traina TA, Dickler MN. Bevacizumab for advanced breast cancer. Womens Health (Lond Engl) 2010;6:17-25.
48. Kane RC, Farrell AT, Tang S, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12:7271-7278.
49. Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009;14:95-100.
50. Heng DY, Rini BI, Garcia J, Wood L, Bukowski RM. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer 2007;5:446-451.
51. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29:1338-1353.